EUVIMEDEUVIMED entdecken
Crossref

Roflumilast and Melatonin Alleviate Acetic Acid‐Induced Ulcerative Colitis via Modulating AMPK/mTOR Signaling, Autophagy‐Related Markers, Intestinal Epithelial Barrier, and NLRP3 Inflammasome

Mohamed I El-Sharkawi, Sousou I Ali, Mohamed A Shaheen, Rana G Eissa iD

Archiv der Pharmazie · 2026-11 · 359 (11)

DOI: 10.1002/ardp.70384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 13.11.2026. Verfasst von Mohamed I El-Sharkawi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Melatonin, Benzamides. Die Arbeit nennt 91 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ulcerative colitis (UC) is a subtype of inflammatory bowel disease affecting the colon and rectum. Our study investigated the therapeutic effects of roflumilast (ROF) or melatonin (MEL) in UC model through modulation of autophagy‐related markers and maintenance of intestinal barrier integrity by targeting AMPK/mTOR signaling, tight junction proteins, and suppressing NLRP3 inflammasome. Twenty‐four male rats were allocated into four groups: Control, UC, ROF, and MEL. UC was induced by injecting acetic acid rectally, followed by oral ROF (5 mg/kg) or MEL (10 mg/kg) for 7 days. Disease activity index (DAI), colon weight/length (W/L) ratio, macroscopic score, histopathological score, and colonic levels of p‐AMPK, mTOR, beclin‐1, p62, occludin, ZO‐1, NLRP3, Caspase‐1, IL‐1β, and IL‐18 were assessed. UC group showed a significant increase in DAI, colon W/L ratio, and macroscopic score. The levels of mTOR, p62, NLRP3, Caspase‐1, IL‐1β, and IL‐18, and histopathological score were significantly increased. While the levels of p‐AMPK, beclin‐1, occludin, and ZO‐1 were significantly decreased compared with the control group. ROF and MEL significantly reversed these changes compared with UC. These findings revealed that ROF and MEL ameliorated experimental UC through modulation of autophagy‐related markers, restoration of the epithelial barrier integrity, and suppression of inflammasome activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeMelatoninBenzamidesAnimalsMaleNLR Family, Pyrin Domain-Containing 3 ProteinTOR Serine-Threonine KinasesRatsSignal TransductionInflammasomesAutophagyAMP-Activated Protein KinasesAcetic AcidCyclopropanesDisease Models, AnimalIntestinal MucosaRats, Sprague-DawleyIntestinal Barrier FunctionAminopyridines

Stichwörter der Autor:innen

AMPKNLRP3 inflammasomeautophagymTORulcerative colitis

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinTOR Serine-Threonine KinasesNlrp3 protein, ratmTOR protein, ratInflammasomesMelatoninAMP-Activated Protein KinasesBenzamidesAcetic AcidRoflumilast

Autor:innen und Institutionen

  • Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
  • Department of Histology & Cell Biology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

ORCID-Profile: Rana G Eissa

Zitieren

APA

El-Sharkawi, M. I., Ali, S. I., Shaheen, M. A., & Eissa, R. G. (2026). Roflumilast and Melatonin Alleviate Acetic Acid‐Induced Ulcerative Colitis via Modulating AMPK/mTOR Signaling, Autophagy‐Related Markers, Intestinal Epithelial Barrier, and NLRP3 Inflammasome. Archiv der Pharmazie, 359(11). https://doi.org/10.1002/ardp.70384

Vancouver

El-Sharkawi MI, Ali SI, Shaheen MA, Eissa RG. Roflumilast and Melatonin Alleviate Acetic Acid‐Induced Ulcerative Colitis via Modulating AMPK/mTOR Signaling, Autophagy‐Related Markers, Intestinal Epithelial Barrier, and NLRP3 Inflammasome. Archiv der Pharmazie. 2026;359(11). doi:10.1002/ardp.70384

BibTeX
@article{ElSharkawi2026,
  author = {El-Sharkawi, Mohamed I and Ali, Sousou I and Shaheen, Mohamed A and Eissa, Rana G},
  title = {Roflumilast and Melatonin Alleviate Acetic Acid‐Induced Ulcerative Colitis via Modulating AMPK/mTOR Signaling, Autophagy‐Related Markers, Intestinal Epithelial Barrier, and NLRP3 Inflammasome},
  journal = {Archiv der Pharmazie},
  year = {2026},
  volume = {359},
  number = {11},
  doi = {10.1002/ardp.70384}
}
Kostenlos starten →